MSMary Ann Sanders

Mary Ann Sanders

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mary Ann Sanders has a total of 123 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Abstract P4-06-07: Clinical risk-assessment, risk-stratification, and outcomes of ER positive, HER2 negative breast cancer patients using the Rochester modified Magee algorithm (RoMMA)

    by Numbereye Numbere, Ioana Moisini, Ajay Dhakal, Kristin Skinner, Michelle Shayne, Mary Ann Gimenez Sanders, Huina Zhang, David Hicks, Bradley M Turner

    INTRODUCTION: In 2013, Klein and Dabbs et al. published three linear regression equations (the new Magee equations) using different combinations of standard histopathologic variables. In 2015, our group published a modification of the new Magee equations. Based on this modification, we published an algorithmic approach using an average Modified Magee equation. This algorithmic approach supported reflex Oncotype DX (ODX) testing based on several cutoff points using an average Modified Magee score. In 2019, we validated this algorithmic approach as the Rochester Modified Magee Algorithm (RoMMA) in a multi-institutional study, with outcome data in 247 patients, suggesting that ER positive breast cancer patients with an average Modified Magee score of ≤ 12 had a low risk of breast cancer recurrence. There has been limited published outcome data on the Magee equation since that 2019 study. We have further refined our risk-stratification approach, with additional outcome data in 416 ER positive breast cancer patients. METHODS: 416 patients with an ODX recurrence score who had at least five years of follow-up data or a breast cancer recurrence were included in the final outcome analysis (2008-2017). All patients received either Tamoxifen or an aromatase inhibitor. None of the patients received adjuvant systemic chemotherapy. The average Modified Magee score was calculated and patients were stratified into four risk-stratification categories: 1) very low, 2) low ≤ 50 years of age, 3) low > 50 years of age, and 4) high. We compared these four risk-stratification categories, with outcomes, between the average Modified Magee score and the ODX recurrence score. A p-value of < 0.05 was considered statistically significant. RESULTS: 27/416 (6.5%) patients had a recurrence of breast cancer. When comparing the same risk category groups, there was no significant difference between the average Modified Magee score and the ODX recurrence score (Table 1). CONCLUSION: Our study further reinforces that breast cancer patients can be confidently stratified into low and high risk recurrence groups using the average Modified Magee score. The average Modified Magee score may be an alternative to ODX for clinical risk-assessment and risk-stratification, particularly in lower risk patients, offering breast cancer patients increased access to clinical risk-assessment and risk-stratification, both domestically and internationally, with a potential significant cost savings for health care systems. A large prospective evaluation, similar to the studies done by ODX, using multi-institutional data or data from studies like the NSABP trial B-14 and the NSABP trial B-20, is necessary. Citation Format: Numbereye Numbere, Ioana Moisini, Ajay Dhakal, Kristin Skinner, Michelle Shayne, Mary Ann Gimenez Sanders, Huina Zhang, David Hicks, Bradley M Turner. Clinical risk-assessment, risk-stratification, and outcomes of ER positive, HER2 negative breast cancer patients using the Rochester modified Magee algorithm (RoMMA) [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-06-07.

  • Open Access

    Chemical carcinogen-induced rat mammary carcinogenesis is a potential model of p21-activated kinase positive female breast cancer

    by Emily L. Duderstadt, Sarah A. McQuaide, Mary Ann Sanders, David J. Samuelson

    The p21-activated kinase 1 ( PAK1) gene encodes a serine/threonine kinase that is overexpressed in a subset of human breast carcinomas with poor prognosis. The laboratory rat ( Rattus norvegicus) orthologous gene is located at Mammary carcinoma susceptibility 3 ( Mcs3) QTL on rat chromosome 1. We used quantitative PCR to determine effects of Mcs3 genotype and 7,12-dimethylbenz(a)anthracene (DMBA) exposure on Pak1 expression. There was no effect of Mcs3 genotype; however, there was a 3.5-fold higher Pak1 level in DMBA-exposed mammary glands (MGs) than in unexposed glands ( P < 0.05). Sequence variants in Pak1 exons did not alter amino acid sequence between Mcs3-susceptible and -resistant strains. Protein expression of PAK1/Pak1 in human breast carcinomas and DMBA-exposed rat mammary glands was detected using immunohistochemistry (IHC). Rat mammary glands from 12-wk-old females unexposed to DMBA were negative for Pak1, whereas 24% of carcinogen-exposed mammary glands from age-matched females stained positive for Pak1. The positive mammary glands exposed to carcinogen had no pathological signs of disease. Human breast carcinomas, used as comparative controls, had a 22% positivity rats. This was consistent with other human breast cancer studies of PAK1 expression. Similar frequencies of human/rat PAK1/Pak1 expression in female breast carcinomas and carcinogen-induced rat mammary glands, showing no visible pathogenesis of disease, suggests aberrant PAK1 expression is an early event in development of some breast cancers. Laboratory rats will be a useful experimental organism for comparative studies of Pak1-mediated mechanisms of breast carcinogenesis. Future studies of PAK1 as a diagnostic marker of early breast disease are warranted.


  • Comparison between two types of needles for Endoscopic Ultrasound (EUS)‐guided fine aspiration biopsy of pancreatic and upper gastrointestinal masses

    by Khaled Alkhateeb, Beatrice B. Lee, Houda Alatassi, Mary A. Sanders, Endashaw M. Omer, Stephen A. McClave, Mostafa Fraig

    Background EUS‐guided fine‐needle aspiration (FNA) has long been the main method for sampling pancreatic lesions. Recently, the method of fine‐needle biopsy (FNB) was introduced in practice, allowing for the acquisition of tissue cores while aspirating the lesion. We hereby report our experience with a new FNB needle compared with the standard FNA needle. Methods Retrospective data from our department were collected on patients who underwent FNB using the Acquire EUS‐FNB needle (Boston Scientific, Massachusetts) and FNA using the EchoTip Ultra EUS‐FNA Needle (Cook Medical, Indiana) between January 2017 and February 2018. The cases were reviewed independently by two cytopathologists and evaluated for the presence of cell block or core tissue material, adequacy for potential ancillary testing, and number of passes. Results The number of passes ranged from 1 to 16, with a mean of 5.52 ± 3.74 in the FNA group, and from 1 to 6, with a mean of 2.74 ± 1.11 passes in the FNB group (P < .0001). Tissue cores were present in 87.23% of the FNB needle samples. A cell block was adequate in 36.36% of cases using the FNA needle. The diagnostic yield as well as the adequacy for ancillary testing were significantly different between the two groups (P = .0001). The tumor size, location and patients' demographics were not statistically significant between the two groups. Conclusion Compared with the conventional needle, the new FNB needle was associated with a lower number of passes and a better yield for histological material.


  • Open Access

    Risk stratification of ER‐positive breast cancer patients: A multi‐institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX® recurrence score <26

    by Bradley M. Turner, Mary Ann Gimenez‐Sanders, Armen Soukiazian, Andrea C. Breaux, Kristin Skinner, Michelle Shayne, Nyrie Soukiazian, Marilyn Ling, David G. Hicks

    The skyrocketing cost of health‐care demands that we question when to use multigene assay testing in the planning of treatment for breast cancer patients. A previously published algorithmic model gave recommendations for which cases to send out for Oncotype DX® (ODX) testing. This study is a multi‐institutional validation of that algorithmic model in 620 additional estrogen receptor positive breast cancer cases, with outcome data on 310 cases, named in this study as the Rochester Modified Magee algorithm (RoMMa). RoMMa correctly predicted 85% (140/164) and 100% (17/17) of cases to have a low‐ or high‐risk ODX recurrence score, respectively, consistent with the original publication. Applying our own risk stratification criteria, in patients who received appropriate hormonal therapy, only one of the 45 (2.0%) patients classified as low risk by our original algorithm have been associated with a breast cancer recurrence over 5‐10 years of follow‐up. Eight of 116 (7.0%) patients classified as low risk by ODX have been associated with a breast cancer recurrence with up to 11 years of follow‐up. In addition, 524 of 537 (98%) cases from our total population (n = 903) with an average modified Magee score ≤18 had an ODX recurrence score 30 may not need to be sent out for ODX testing. By avoiding these cases sending out for ODX testing, the potential cost savings to the health‐care system in 2018 are estimated to have been over $100,000,000.


  • Evaluating the relationship between ductal carcinoma in situ, calcifications, and margin status in patients undergoing breast conserving surgery

    by Elizabeth H. Bruenderman, Neal Bhutiani, Megan K. Mercer, Kelly M. McMasters, Mary Ann G. Sanders, Nico Lás Ajkay

    Background: Microcalcifications associated with ductal carcinoma in situ (DCIS‐AMC) close to lumpectomy margins could be used as a surrogate for margin involvement and aid in decreasing margin re‐excision. We sought to evaluate the histologic factors of DCIS‐AMC near lumpectomy margins.Methods: Women with DCIS treated with breast‐conserving surgery (BCS) who had DCIS‐AMC on surgical specimens were identified. Pathology slides were reviewed to determine the distance of DCIS‐AMC from each margin (six per specimen) and the distance of DCIS from each margin (ie, margin status).Results: Of 35 patients (210 margins), 24 had close/positive margins (39 margins [18%]). DCIS‐AMC≤10 mm from a margin was associated with a greater incidence of DCIS≤2 mm from the margin (31.7% DCIS‐AMC≤10 mm vs 13.3% no DCIS‐AMC≤10 mm, P = 0.003). On multivariable analysis, DCIS≤2 mm from the margin was independently associated with DCIS‐AMC≤10 mm from the margin (odds ratio 2.95, 95% confidence interval 1.48‐5.86, P = 0.002).Conclusions: DCIS‐AMC≤10 mm from the inked margin is associated with DCIS at or close to the margin (≤2 mm). Using this knowledge, intraoperative techniques like specimen radiography could be utilized to detect microcalcifications≤10 mm from a margin and guide selective margin re‐excision in BCS.


  • Impact of 21-Gene Expression Assay on Staging Estrogen Receptor–Positive HER2-Negative Breast Cancer

    by Andrea Breaux, Bradley Turner, Xiaoyong Wu, Shesh N. Rai, Elizabeth C. Riley, Mounika Mandadi, Mary Ann Sanders


  • Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery

    by Mirna B. Podoll, Emily S. Reisenbichler, Lania Roland, Andrew Bruner, Sarah Mizuguchi, Mary Ann G. Sanders

    Context.—: Ductal carcinoma in situ (DCIS) represents 20% of screen-detected breast cancers. The likelihood that certain types of DCIS are slow growing and may never progress to invasion suggests that our current standards of treating DCIS could result in overtreatment. The LORIS (LOw RISk DCIS) and LORD (LOw Risk DCIS) trials address these concerns by randomizing patients with low-risk DCIS to either active surveillance or conventional treatment. Objective.—: To determine the upgrade rate of DCIS diagnosed on core needle biopsy to invasive carcinoma at surgery and to evaluate the safety of managing low-risk DCIS with surveillance alone, by characterizing the pathologic and clinical features of upgraded cases and applying criteria of the LORD and LORIS trials to these cases. Design.—: A 10-year retrospective analysis of DCIS on core needle biopsy with subsequent surgery. Results.—: We identified 1271 cases of DCIS on core needle biopsy: 200 (16%) low grade, 649 (51%) intermediate grade, and 422 (33%) high grade. Of the 1271 cases, we found an 8% upgrade rate to invasive carcinoma (n = 105). Nineteen of the 105 upgraded cases (18%) had positive lymph nodes. Low-grade DCIS was least likely to upgrade to invasion, comprising 10% (10 of 105) of upgraded cases. Three of the 105 upgraded cases (3%) met criteria for the LORD trial, and all were low-grade DCIS on core needle biopsy with favorable biology on follow-up. Conclusions.—: There is a clear risk of upgrade to invasion on follow-up excision; however, applying strict criteria of the LORD trial effectively decreases the likelihood of a missed invasive component or missed aggressive pathologic features.


  • Nipple-Invasive Primary Carcinomas: Clinical, Imaging, and Pathologic Features of Breast Carcinomas Originating in the Nipple

    by Mary Ann Sanders, Jane E. Brock, Beth T. Harrison, Tad J. Wieczorek, Xuefei Hong, Anthony J. Guidi, Deborah A. Dillon, Leslie Max, Susan C. Lester

    Context: Patients choosing to retain the nipple when undergoing therapeutic or prophylactic mastectomy are at risk for cancers arising at that site. Objective: To identify cases of invasive carcinoma arising within the nipple and to investigate their clinical, imaging, biologic, and staging features. Design: Carcinomas were identified by prospective review of surgical and consult cases at 4 hospitals. Results: The 24 patients identified presented with symptoms related to the nipple. Mammography did not detect the cancer in most cases. Ten patients (42%) had skin changes from ductal carcinoma in situ involving nipple skin (Paget disease), with small foci of invasion into the dermis, and 6 of those 10 carcinomas (60%) stained positive for human epidermal growth factor receptor 2 (HER2). The remaining 14 patients (58%) presented with a nipple mass or with skin changes. These were larger invasive carcinomas of both ductal and lobular types. Only 2 of those 14 carcinomas (14%) were HER2+. Three of 15 patients (20%) undergoing lymph node biopsy had a single metastasis. No patients have had recurrent disease. Conclusions: Rare, invasive, primary nipple carcinomas typically present as subtle nipple thickening or an exudative crust on the skin. Imaging studies are often nonrevealing. A variety of histologic and biologic types of carcinomas occur, similar to cancers arising deeper in the breast. Although the carcinomas invaded into the dermis, some with skin ulceration, the likelihood of lymph node metastasis was no higher than carcinomas of similar sizes. Patients who choose to preserve their nipple(s) should be aware of the possibility of breast cancer arising at that site and to bring any observed changes to the attention of their health care providers.


  • Association of HIPEC with survival in patients with ovarian metastases of gastrointestinal origin.

    by Srividya Srinivasamaharaj, Dhruv Ranchhodbhai Chaudhary, Xiaoyong Wu, Shesh Rai, Mary Ann Sanders, Rebecca A. Redman

    E15124 Background: Metastatic ovarian involvement in primary gastrointestinal (GI) carcinomas (CA) is associated with a poor prognosis. We performed a survival analysis in patients with ovarian metastases, based on site of primary GI CA (appendiceal, colorectal (CRC), gastric, and pancreatic). We also examined the association between hyperthermic intraperitoneal chemotherapy (HIPEC) and death in these patients. Methods: A search was conducted in a single institution pathology database for patients with primary GI CA and ovarian metastases diagnosed from 2010 to 2017. The search yielded 39 patients, and data pertaining to tumor characteristics and treatment were obtained by chart review. Chi-square (log rank) test was used to test for associations between both site of primary GI CA and HIPEC, and death, and Kaplan-Meier analysis was done. P-value < 0.05 was deemed statistically significant. Results: CRC accounted for the majority of patients (51.29%) with appendiceal CA accounting for 23.08% and gastric and pancreatic cancer making up the remainder. Primary site of malignancy was associated with survival (p = 0.036), favoring those with appendiceal and colorectal primaries. A total of 30 patients (76.92%) received HIPEC. Having undergone HIPEC was significantly associated with survival (p = 0.017). Conclusions: Ovarian metastases secondary to gastric and pancreatic cancer were associated with inferior survival as compared to those with appendiceal or colorectal primaries. A significant association was demonstrated between HIPEC and survival. Further investigation to define the role of HIPEC in the treatment of carcinomas of gastrointestinal primaries is warranted.